Psyence Biomedical Announces 1-For-75 Share Consolidation Will Begin Trading On A Post-Consolidated Basis At The Opening Of The Market On Tuesday, November 26, 2024
Psyence Biomedical Announces 1-For-75 Share Consolidation Will Begin Trading On A Post-Consolidated Basis At The Opening Of The Market On Tuesday, November 26, 2024
Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced an effective date for its previously-announced share consolidation. At its Annual General and Special Meeting of Shareholders, which was held on November 12, 2024, Psyence Biomed's shareholders approved a consolidation of the Company's common shares at a ratio of up to 1 common share for every 75 common shares held, with the final ratio to be determined by the Company's board of directors (the "Board"). Also, as previously announced, the Board approved a 1-for-75 consolidation of its outstanding common shares.
Psyence Biomedical Ltd.（纳斯达克代码：PBM）（"Psyence Biomed" 或 "公司"）今天宣布了股份合并的有效日期。在 2024 年 11 月 12 日举行的股东大会上，Psyence Biomed 的股东批准了按照最多每 75 个持有的普通股合并 1 股的方案，最终比例将由公司董事会（"董事会"）确定。与此前宣布的一样，董事会批准了对其流通普通股进行 1:75 的合并。
The Company's common shares will begin trading on a post-consolidated basis at the opening of the market on Tuesday, November 26, 2024. Following the consolidation, the Company's common shares will continue to trade under the symbol 'PBM' with the new CUSIP number 74449F209. The consolidation is part of the Company's plan to regain compliance with the minimum bid price requirement of Nasdaq Listing Rule 5450(a)(1) (the "Nasdaq Rule 5450") for continued listing on The Nasdaq Global Market.
公司的普通股将从 2024 年 11 月 26 日星期二市场开盘后开始进行合并交易。合并后，公司的普通股将继续以符号 'PBM' 进行交易，新的CUSIP编号为 74449F209。这次合并是公司为恢复符合纳斯达克股票上市规则 5450(a)(1)（"纳斯达克规则 5450"）的最低买盘价格要求而进行的计划。
